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E-mail address: jyolee@hallym.ac.kr (J.-Y. Lee).To examine the function of SIRT1 in neuronal differentiation, we employed all-trans retinoic acid
(ATRA)-induced differentiation of neuroblastoma cells. Nicotinamide inhibited neurite outgrowth
and tyrosine hydroxylase (TH) expression. Inhibition of PARP or histone deacetylase did not inhibit
TH expression, showing the effect to be SIRT1 speciﬁc. Expression of FOXO3a and its target proteins
were increased during the differentiation and reduced by nicotinamide. FOXO3a deacetylation was
increased by ATRA and blocked by nicotinamide. SIRT1 and FOXO3a siRNA inhibited ATRA-induced
up-regulation of TH and differentiation. Taken together, these results indicate that SIRT1 is involved
in ATRA-induced differentiation of neuroblastoma cells via FOXO3a.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Among mammalian sirtuins, SIRT1 has been characterized the
most extensively. SIRT1 deacetylates transcription factors (p53,
FOXOs, Ku70, NFkB, etc.) in the nucleus, and thus functions in
cell differentiation, cell survival, tumorigenesis and metabolism.
SIRT1 plays a role in differentiation of skeletal muscles, adipo-
cytes, and pancreatic-beta cells [1,2]. In addition to metabolic or-
gans, SIRT1 also promotes the differentiation of spermatogenesis
[3]. SIRT1 is ubiquitously expressed but predominantly expressed
in brain and heart during middle to late developmental periods
[2,4]. There have some reports that SIRT1 prevents axonal degen-
eration during brain injury and inhibits some neurological toxicchemical Societies. Published by E
iochemistry, College of Med-
Gangwon-do 200-702, Southinsults in animal models of Alzheimer’s disease and amyotrophic
lateral sclerosis [5,6]. Recently, it was reported that SIRT is in-
volved in redox-dependent fate of neural progenitors [7], and
that SIRT1 plays an important role in differentiation of neural
precursor cells through translocation into the nucleus [8]. How-
ever, the direct involvement of SIRT1 in neuronal differentiation
has not been characterized.
The class O subfamily of forkhead box (FOXO) transcription fac-
tors – FOXO1, FOXO3a, FOXO4, and FOXO6 – is known to play var-
ious roles in mammalian cells including in differentiation,
metabolism, proliferation, and survival [9,10]. Gene targeting
experiments in mice showed that FOXO1a regulates developmen-
tal vascular formation, insulin sensitivity, and adipocyte differenti-
ation, while FOXO3a regulates ovarian development and fertility
[11–13]. FOXO proteins are also important for myoblast fusion or
muscle differentiation and skeletal atrophy [14]. However, the
involvement of FOXO in neuronal differentiation has not been re-
ported so far.lsevier B.V. All rights reserved.
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Deacetylated FOXO protein may exert different transcriptional
activities in response to stress. But, there have been conﬂicting re-
ports regarding the effects of SIRT1 on FOXO3- and FOXO4-induced
p27 expression, depending on cell or tissue types. Motta et al.
showed repression of p27 transcription while Brunet et al. and
van der Horst et al. reported activation [15–17]. FOXO3a was
shown to be phosphorylated on eight sites and acetylated on ﬁve
sites induced by oxidative damage [15].
In the present study, we investigated the function of SIRT1 and
FOXO3a in ATRA-induced differentiation of neuroblastoma cells.
We found that SIRT1 up-regulates TH expression and induces neu-
ronal differentiation via FOXO3a, suggesting that FOXO3a and its
regulator SIRT1 play important roles in neuronal differentiation.
2. Materials and methods
2.1. Cell culture
The human neuroblastoma cell lines SH-SY5Y and Neu2A were
purchased from the ATCC (USA). Cells were cultivated in DMEM
supplemented with 10% FBS (BioWhitaker, USA) at 37 C in a
humidiﬁed atmosphere containing 5% CO2. Cells were plated at
50–60% of conﬂuence.
2.2. Plasmid preparation
For silencing human FOXO3a, target sequences (siFOXO3a#1;
50-ACTCCGGGTCCAGCTCCAC-30) and (siFOXO3a#2; 50-GAGCTC
TTGGTGGATCATC-30) [18] were ligated into pSIREN-RetroQ-DsRed
vector (Invitrogen, USA). For human SIRT1 the target sequences
were (siSIRT1#1; 50-GATGAAGTTGACCTCCTCA-30) [19] and
(siSIRT1#2; 50-CTGGAGCTGGGGTGTCTG-30). The scrambed siRNA
sequence is 50-CCT ACG CCA CCA ATT TCG T-3.
2.3. Western blot analysis and immunoprecipitation
For Western blot analysis, cells were harvested in a 10 mM Tris
(pH 7.4) buffer containing 1% SDS and 1 mM Na3VO4. After SDS–
PAGE, the proteins were transferred onto nitrocellulose membrane.
The membrane was incubated with primary antibodies and then
with horseradish peroxidase-conjugated secondary antibodies.
The antigenwas visualized by chemiluminescent substrates (Amer-
sham, USA). For immunoprecipitation of acetylated FOXO3a, cells
were lysed in a 50 mM Tris buffer, pH 7.4 containing 150 mM NaCl,
5 mM EDTA, 1% NP40 and protease inhibitors (10 lg/ml aprotinin,
10 lg/ml leupeptin, and 4 mMPMSF). Lysates were immunoprecip-
itatedwith FOXO3a antibody andwere probed byWestern blotting.
Primary antibodies used for immunoblotting were anti-actin (Sig-
ma, USA; #A3853), anti-SIRT1 (Santa Cruz, USA; #sc-15404), anti-
p27 (Santa Cruz, USA; #sc-6141), anti-FOXO1a (Cell Signal, USA;
#9462), anti-FOXO4 (Santa Cruz, USA; #sc-5224), anti-FOXO3a
(Cell Signal, USA; #2497), anti-MnSOD (Calbiochem, USA;
#574596), and anti-p130 (LabVision, USA; #MS-866-P).Fig. 1. Nicotinamide inhibits ATRA-induced differentiation of neuroblastoma cells.
(A) Morphology of untreated (left), ATRA-treated (middle) and ATRA and nicotin-
amide-treated (right) SH-SY5Y cells are presented. Nicotinamide (NAM) (10 mM)
was co-treated with 10 lM ATRA in SH-SY5Y cells for 3 days (400 magniﬁcation).
(B) RT-PCR analysis of TH and NFM RNA transcripts after SH-SY5Y cells were treated
with/without ATRA and nicotinamide. (C) Quantiﬁcation of RT-PCR product bands.
The ratio of TH/NFM to GAPDH is shown as the mean ± SEM of the triplicate
experiments and statistical signiﬁcance is indicated as *p < 0.05 and **p < 0.01 by
Student’s t-test.2.4. Transient transfection and promoter assay
About 1.4-kb fragment of the human TH gene, spanning the re-
gion 1352 to +30 bp from the transcription initiation site, was
ampliﬁed by PCR and sub-cloned into pGL3-basic vector (Promega,
USA). The promoter construct and pCS-beta-gal were transfected
into cells using Lipofectamine (Invitrogen, USA). After ATRA treat-
ment, the cells were collected in Cell Lysis Reagent (Promega, USA),
and assayed for luciferase activity. b-galactosidase expression was
measured to normalize for transfection efﬁciency.2.5. RNA isolation and analysis
Total RNA was extracted using Trizol Reagent (Invitrogen, USA).
To examine FOXO3a, TH, and NFM mRNA expressions, 1 lg of total
RNA was reverse-transcribed and ampliﬁed using the cDNA syn-
thesis kit (Takara, Japan). TH, NFM and GAPDH were ampliﬁed
simultaneously with the following oligonucleotides: TH-F (50-
AGTGCACCCAGTATATCCGCC-30), TH-R (50-GACACGAAGTAGACTGA
CTGGTACGTC-30), NFM-F (50-TGGGAAATGGCTCGTCATTT-30), NF
M-R (50-CTTCATGGAAGCGGCCAATT-30), GAPDH-F (50-AACATCATC
CCTGCCTCTAC-30), and GAPDH-R (50-TCTCTCTCTTCCTCTTGTGC-
30). For PCR reactions, Taq polymerase (Roche, USA) was used for
28–32 cycles and then each sample was analyzed by electrophore-
sis and staining with ethidium bromide.
3. Results
3.1. Nicotinamide inhibits differentiation and up-regulation of TH in
ATRA-treated neuroblastoma cells
To investigate the effect of nicotinamide on neuronal cell differ-
entiation, we examined the ATRA-treated SH-SY5Y neuroblasoma
cells. ATRA treatment at 10 lM changed the morphology, with
elongated neurites appearing after 3–5 days (Fig. 1A). Nicotin-
amide, a SIRT1 inhibitor, inhibited differentiation of SH-SY5Y cells
(Fig. 1A). The levels of TH and NFM mRNAs, neuron speciﬁc mark-
ers, were increased in ATRA-treated SH-SY5Y cells (Fig. 1B and C)
as shown in a previous report [20]. Nicotinamide treatment re-
versed the increased levels of TH and NFM mRNAs. These results
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roblastoma cells and expression of neuronal markers.
3.2. Nicotinamide inhibits ATRA-induced up-regulation of TH via
inhibition of SIRT1
To investigate how nicotinamide inhibits up-regulation of TH, a
reporter construct containing human TH promoter sequences was
used. In the differentiated SH-SY5Y cells induced by ATRA, TH pro-
moter activity was increased 2–3-fold (Fig. 2A). To verify whether
the inhibitory effect of nicotinamide on ATRA-induced up- regula-
tion of TH is SIRT1-dependent, we tested the effects of benzamide
and Trichostatin A (TSA), which are inhibitors of PARP (another
NAD-dependent enzyme) and class I & II histone deacetylase,
respectively (Fig. 2A). As expected, nicotinamide reduced the TH
promoter activity in ATRA-treated cells in a dose dependent man-
ner, but benzamide did not change the TH promoter activity. TSA
(100 nM) fails to increase TH promoter activity, which may be
caused by TSA-induced growth arrest or cell death as previous
reported [21]. Moreover, the inhibition of HDAC by TSA rather in-
creased TH promoter activity even though both HDAC and SIRT1
have similar deacetylase activities.
To conﬁrm further that the effect of nicotinamide in ATRA-
induced differentiation is SIRT1-speciﬁc, two SIRT1 siRNAs were
transfected transiently and then TH promoter activity was mea-
sured after ATRA treatment. Because of the low transfection efﬁ-
ciency of human SH-SY5Y neuroblastoma cells, we tested several
SIRT1 siRNA clones in HEK293 cells (Fig. 2B). The SIRT1 siRNAs de-
creased TH promoter activity in ATRA-treated SH-SY5Y cells
(Fig. 2C) and inhibited the ATRA-induced change in morphology,
resulting in cells with a ﬂat and round shape (‘‘S-type” morphol-Fig. 2. SIRT1 is associated with TH expression and morphological change in ATRA-indu
activities) in SH-SY5Y cells were measured using luciferase assay after 3 days of 10 lM A
are used as inhibitors of PARP and HDAC, respectively. (B) Western blot analysis of SIRT
(relative luciferase activities) and (D) differentiated morphology of SH-SY5Y cells transf
DsRed, 0.5 lg) 3 days after ATRA treatment. (E) TH promoter activities (relative luciferas
promoter assays were repeated twice with triplicate experiments a batch. The ratio o
mean ± SEM of triplicate experiments and statistical signiﬁcance is indicated as *p < 0.05ogy) (Fig. 2D). After transfection with SIRT1 siRNAs, the undifferen-
tiated, S-type morphology was seen in over 90% of transfected
population after 3 days, whereas cells transfected scrambled siRNA
showed the differentiated N-type morphology. We also tested TH
promoter activity after transfection of wild type SIRT1 and a dom-
inant-negative SIRT1. Transfection of wild type SIRT1 has no addi-
tive effect in ATRA-treated cells, but a dominant-negative SIRT1
showed considerable down-regulation of TH promoter activity
(Fig. 2E). These results suggest that the inhibitory effect of nicotin-
amide on ATRA-induced up-regulation of TH is SIRT1-dependent.
3.3. SIRT1 plays an important role via FOXO3a in ATRA-induced
differentiation of neuroblastoma cells
FOXO families have been shown to be deacetylated by SIRT1
[15–17]. We ﬁrst tested protein levels of previously reported FOXO
target genes (p27, p130, and MnSOD) in SH-SY5Y cells at various
times after ATRA treatment (Fig. 3A and B) [10]. The levels of the
target proteins were increased after 1 day of ATRA treatment. Also,
FOXO3a and FOXO4 increased in ATRA-induced differentiation of
SH-SY5Y cells (Fig. 3A). The increase of FOXO3a level started one
day after treatment with ATRA and continued up to 3 days, while
FOXO4 was transiently increased at 3–6 h after treatment of ATRA.
FOXO1a was not induced by ATRA. Therefore, since the target pro-
teins of FOXOs were increased after 1 day of ATRA treatment, we
speculated that the up-regulation of FOXO3a was strongly associ-
ated with the ATRA-induced differentiation of SH-SY5Y cells. FOX-
O3a was previously reported to be up-regulated 9-fold in SH-SY5Y
cells after 6 days of differentiation induced by ATRA [22]. However,
in our settings, no remarkable change in protein expression was
found between 3 and 5 days of differentiation (data not shown).ced differentiation of SH-SY5Y cells. (A) TH promoter activities (relative luciferase
TRA treatment. Benzamide (Benz, 0.5–5 mM) and Trichostatin A (TSA, 10–100 nM)
1 24 h after transfection of SIRT1 siRNA in HEK293 cells. (C) TH promoter activities
ected with control scrambled (sc) and SIRT1 (#1 and #2) siRNAs (pSIREN-RetroQ-
e activities) of SH-SY5Y cells transfected with WT-SIRT1 and DN-SIRT1 (0.5 lg). All
f relative luciferase and b-galactosidase activities to the control is shown as the
and **p < 0.01 by Student’s t-test.
Fig. 3. The expression level and the deacetylation status of FOXO3a are correlated
with ATRA-induced differentiation of SH-SY5Y. SH-SY5Y cells were treated with
10 lM ATRA treatment for 3 days. (A, B) The levels of FOXO subfamily (FOXO1a,
FOXO3a, and FOXO4), FOXO target proteins (p27, p130, and MnSOD), and SIRT1
during ATRA-induced differentiation were analyzed by (A) Western blot analysis
and (B) densitometric analysis. (C) FOXO3a was immunoprecipitated with anti-
FOXO3a antibody and analyzed by Western blot analysis with anti-acetyl-lysine
antibody.
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acetyl lysine antibody to investigate how SIRT1 affects FOXO3a.
FOXO3a was deacetylated in ATRA-treated SH-SY5Y cells com-
pared to untreated cells. This deacetylation was inhibited by nico-
tinamide (Fig. 3C).
To determine whether FOXO3a is involved in regulation of TH
expression, we knocked down FOXO3a using siRNAs. The promoter
activity of TH was decreased by two different FOXO3a siRNAs
(Fig. 4B). The decrease in FOXO3a by siRNAs prevented differenti-
ation to an elongated N-type morphology, just as was seen with
SIRT1 siRNAs (Figs. 2D and 4D). Therefore, FOXO3a could be an
important mediator for ATRA-induced differentiation as well as
ATRA-induced up-regulation of TH in SH-SY5Y cells. We also tested
promoter activity of MnSOD, which is a target gene of FOXO3a. As
expected, the promoter activity of MnSOD was decreased by trans-
fection of FOXO3a siRNAs (Fig. 4C). Similarly, MnSOD promoter
activity was increased by treatment with ATRA and decreased by
treatment with nicotinamide or by transfection of DN-SIRT1
(Fig. 4E). The levels of p27, p130, and MnSOD were also decreased
in nicotinamide-treated cells when compared to the cells treated
only with ATRA (Fig. 4F).
4. Discussion
Since direct involvement of SIRT1 and FOXO in neuronal
differentiation has not been characterized yet, we tested the
involvement of SIRT1 and FOXO in ATRA-induced neuronal differ-
entiation of neuroblastoma cells. In this study, we demonstrated
using nicotinamide, a dominant-negative SIRT1, SIRT1 siRNAs,
and FOXO siRNAs that SIRT1 is involved in ATRA-induced up-regu-
lation of TH and differentiation of neuroblastoma cells via FOXO3a.
Mammalian SIRT1 is a NAD-dependent deacetylase and classiﬁed
as class III HDAC. Class III HDAC is different from class I & II HDACs
that are inhibited by classical HDAC inhibitors such as sodium
butyrate and TSA [1,2]. There have been several reports that HDAC
inhibition induces neurogenesis and neuronal differentiation.Valproic acid, a HDAC inhibitor, induced neuronal differentiation
of adult hippocampal neural progenitors via the regulation of Neu-
roD. TSA mediated the differentiation of Neuro2A neuroblastoma
cells via cell cycle arrest [23,24]. Our results showed that nicotin-
amide inhibited ATRA-induced differentiation of neuroblastoma
cells and the expression of TH, but TSA had no effect, indicating
that the inhibitory effect of nicotinamide is due to SIRT1 inhibition.
TH promoter activity in ATRA-induced differentiation was inhib-
ited by nicotinamide and increased by TSA, which demonstrates
the opposite role of classical HDAC and SIRT1. Activation of TH
transcription by TSA and sodium butyrate was reported before
[25]. In addition, the effect of SIRT1 in ATRA-induced differentia-
tion seems to be through its enzymatic activation rather than its
expression level. The level of SIRT1 was constant throughout ATRA
treatment (Fig. 3A). Because there was a recent report that the ac-
tive regulator of SIRT1 (AROS) regulates p53 activity via SIRT1, it is
quite possible that the mechanism to regulate SIRT1 activity may
be involved here [26]. Therefore, we concluded that SIRT1 is a no-
vel regulator of neuronal differentiation and TH expression.
FOXO3a is inactivated through phosphorylation (Thr32, Ser253,
and Ser315) by Akt [15,27]. This modiﬁcation of FOXO3a is a major
regulatory pathway to execute various cellular functions. However,
the phosphorylation of FOXO3a at Thr32 was not decreased but
rather increased unexpectedly in ATRA-induced differentiation of
neuroblastoma cells (data not shown). Thus, the activation of FOX-
O3a via dephosphorylation may not be the cause of ATRA-induced
differentiation of neuroblastoma cells. Our results showed that in-
stead the deacetylation of FOXO3a by SIRT1 leads to activation of
FOXO3a, and is clearly responsible for ATRA-induced differentia-
tion of neuroblastoma cells. In addition, when we transfected a
deacetylation-mimic FOXO3a (K241R/K289R/K568R) in ATRA-
induced differentiation of neuroblastoma cells, the promoter activ-
ity of TH was increased as expected when compared to wild type
FOXO3a, conﬁrming that acetylation/deacetylation is important
(Supplementary Fig. 1). Further detailed characterization of IGF1/
PI3K/Akt/FOXO3a signaling pathways in ATRA-induced differentia-
tion of neuroblastoma cells will address this question. In addition,
we found an increase of FOXO3a expression in ATRA-induced dif-
ferentiation. The increased FOXO3a is deacetylated by SIRT1
(Fig. 3C), but its expression was not changed by nicotinamide treat-
ment (Fig. 4E). Therefore, FOXO3a expression in ATRA-induced dif-
ferentiation seems to be independent of SIRT1 activity and could
be caused by RNA increase via other or unknown transcriptional
machinery (Supplementary Fig. 2).
The expression pattern of TH was similar to that of FOXO3a tar-
get genes such as MnSOD and p130 in SH-SY5Y (Fig. 3A). TH mRNA
was increased by ATRA treatment and decreased by co-treatment
of nicotinamide (Fig. 1). This effect of ATRA treatment was de-
creased by additional treatment with nicotinamide, SIRT1 siRNAs,
DN-SIRT1, and FOXO3a siRNAs (Figs. 2 and 4). Therefore, we con-
sidered the possibility that TH is a direct target gene of FOXO3a.
We attempted to verify this, but the overexpression of FOXO3a
did not increase TH promoter activity in either untreated control
or ATRA-treated SH-SY5Y and Neu2A cells (data not shown). The
possible explanations are: (i) FOXO3a alone may not activate TH
promoter and other transcription factor(s) might be required. It
has been reported that FOXO3a interacts with other factors, such
as retinoic acid receptor, estrogen receptor, or progesterone recep-
tor, to activate or inactivate its own transcriptional activity [28].
FOXO3a has also been reported to represses transcriptional activity
of HNF4a through formation of a heterodimer with HNF4a [29].
Further identiﬁcation and characterization of additional factors
will prove this hypothesis. (ii) FOXO3a may be responsible for late
maintenance of ATRA-induced differentiation, but not for the initi-
ation of differentiation. The protein levels of FOXO3a and its target
genes were increased in 1–2 days after ATRA treatment (Fig. 3A).
Fig. 4. FOXO3a is associated with TH expression and morphological change in ATRA-induced differentiation of SH-SY5Y cells. SH-SY5Y cells were treated with 10 lM ATRA
treatment for 3 days. (A) Western blot analysis of FOXO3a 24 h after transfection of FOXO3a siRNA in HEK293 cells. (B) TH promoter activities and (C) MnSOD promoter
activities were measured using luciferase assay 24 h after transfection of 0.5 lg FOXO3a siRNA following 3 days of ATRA treatment. (D) Morphology of SH-SY5Y cells 24 h
after transfection of 0.5 lg FOXO3a siRNA following 3 days of ATRA treatment. (F) MnSOD promoter activities were measured using luciferase assays 24 h after transfection of
0.5 lg WT/DN-SIRT1 following 3 days of ATRA treatment. NAM (10 mM) and 10 lM TSA were co-treated with ATRA. (F) Western blot analysis showing the levels of FOXO3a
and its target proteins after treatment with ATRA and nicotinamide. All promoter assays were repeated twice with triplicate experiments a batch. The ratio of relative
luciferase activities to the control is shown as the mean ± SEM of triplicate experiments and statistical signiﬁcance is indicated as **p < 0.01 and ***p < 0.001 by Student’s t-test.
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lowing activation of early response genes in ATRA-induced neuro-
blastoma differentiation. The exact time course of FOXO3a
activation or inactivation should be tested to address this hypoth-
esis. In addition, the activity of TH promoter in ATRA-induced dif-
ferentiation was somewhat different from that of the MnSOD
promoter, in that after transfection of DN-SIRT1 TSA activated
the TH promoter but not the MnSOD promoter (Figs. 2E and 4E).
Thus, TH promoter may be regulated by other transcription factors
in addition to FOXO3a.
Despite that it is still debatable whether TH is a transcriptional
target of FOXO3a, we clearly veriﬁed that the deacetylation of FOX-
O3a by SIRT1 is required for ATRA-induced differentiation of neu-
roblastoma cells. SIRT1 turned out to be an important regulator of
ATRA-induced differentiation in neuroblastoma cells, affecting
both the morphology changes and the expression of TH. FOXO3a
acts as a downstream transcription factor of SIRT1. We believe that
further investigation using transgenic animals will provide better
understanding of the roles of SIRT1 and FOXO3a in the develop-
ment and function of mammalian brain.
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